ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 992,87
0,18%
Dow Jones
38 686,32
1,51%
DAX
18 497,94
-0,09%
Brent Oil
81,295
0,00%
Bitcoin
67 787,99
0,45%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Dicerna Pharmaceuticals Inc (DRNA)

  7. Dicerna Pharmaceuticals Inc (DRNA) Actualités

DRNA

Dicerna Pharmaceuticals (DRNA)

Dicerna Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:DRNA
DateHeureSourceTitreSymboleSociété
14/02/202212h18Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:DRNADicerna Pharmaceuticals Inc
10/01/202223h00Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(b) (15-12b)NASDAQ:DRNADicerna Pharmaceuticals Inc
03/01/202212h03Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:DRNADicerna Pharmaceuticals Inc
29/12/202122h23Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:DRNADicerna Pharmaceuticals Inc
28/12/202117h18Edgar (US Regulatory)Post-effective Amendment to an Automatic Shelf Registration of Form S-3asr or Form F-3asr (posasr)NASDAQ:DRNADicerna Pharmaceuticals Inc
28/12/202117h15Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:DRNADicerna Pharmaceuticals Inc
28/12/202117h06Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:DRNADicerna Pharmaceuticals Inc
28/12/202116h52Edgar (US Regulatory)Amended Statement of Ownership: Solicitation (sc 14d9/a)NASDAQ:DRNADicerna Pharmaceuticals Inc
28/12/202116h47Edgar (US Regulatory)Amended Tender Offer Statement by Third Party (sc To-t/a)NASDAQ:DRNADicerna Pharmaceuticals Inc
28/12/202115h35Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:DRNADicerna Pharmaceuticals Inc
28/12/202115h29Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:DRNADicerna Pharmaceuticals Inc
28/12/202115h04Business WireNovo Nordisk Announces Completion of Dicerna Pharmaceuticals AcquisitionNASDAQ:DRNADicerna Pharmaceuticals Inc
25/12/202114h00Business WireDicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire DicernaNASDAQ:DRNADicerna Pharmaceuticals Inc
09/12/202114h41PR Newswire (US)Direxion Launches mRNA ETF (MSGR)NASDAQ:DRNADicerna Pharmaceuticals Inc
09/12/202100h55TipRanksDicerna Pharma (DRNA) Gets a Hold Rating from Chardan CapitalNASDAQ:DRNADicerna Pharmaceuticals Inc
25/11/202110h09TipRanksLeerink Partners Keeps a Buy Rating on Dicerna Pharma (DRNA)NASDAQ:DRNADicerna Pharmaceuticals Inc
24/11/202123h07Edgar (US Regulatory)Statement of Ownership: Solicitation (sc 14d9)NASDAQ:DRNADicerna Pharmaceuticals Inc
24/11/202122h58Edgar (US Regulatory)Tender Offer Statement by Third Party (sc To-t)NASDAQ:DRNADicerna Pharmaceuticals Inc
19/11/202113h16TipRanksDicerna Soars 78.7% on Novo Nordisk’s $3.3B Acquisition OfferNASDAQ:DRNADicerna Pharmaceuticals Inc
18/11/202123h32Edgar (US Regulatory)Written Communication Relating to an Issuer or Third Party (sc To-c)NASDAQ:DRNADicerna Pharmaceuticals Inc
18/11/202123h08Edgar (US Regulatory)Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c)NASDAQ:DRNADicerna Pharmaceuticals Inc
18/11/202117h47Dow Jones NewsDicerna Shares Soar on Takeover by Novo NordiskNASDAQ:DRNADicerna Pharmaceuticals Inc
18/11/202113h51Dow Jones NewsNovo Nordisk to Buy Dicerna for $38.25 a ShareNASDAQ:DRNADicerna Pharmaceuticals Inc
18/11/202113h00Business WireNovo Nordisk to Acquire DicernaNASDAQ:DRNADicerna Pharmaceuticals Inc
12/11/202114h54Dow Jones NewsDicerna Pharma: Two Targets in Lilly Collaboration Meet Proof of PrincipleNASDAQ:DRNADicerna Pharmaceuticals Inc
12/11/202114h10Business WireDicerna Announces Two Targets Meet Preclinical Proof of Principle Criteria in Neurodegeneration and Pain Under Global Research Collaboration and Licensing Agreement With LillyNASDAQ:DRNADicerna Pharmaceuticals Inc
12/11/202114h00Business WireDicerna Presents Data From Phase 1 Trial of Belcesiran at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021NASDAQ:DRNADicerna Pharmaceuticals Inc
09/11/202113h50Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:DRNADicerna Pharmaceuticals Inc
09/11/202113h30Business WireDicerna Announces Third Quarter 2021 Financial Results and Provides a Business UpdateNASDAQ:DRNADicerna Pharmaceuticals Inc
04/11/202118h15Business Wire Dicerna Presents PHYOX™2 and Primary Hyperoxaluria Healthcare Utilization Data at American Society of Nephrology (ASN) Kidney Week 2021NASDAQ:DRNADicerna Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:DRNA

Dernières Valeurs Consultées

LSE
VJPB
Vanftsejapan
NYSE
SCD
LMP Capital and Income
BIT
UC5F5Z
Unicredit Bank
LSE
23FD
Asb Fin.21
BIT
Q00599
Leonteq Securities
EU
TTGCL
Tagus Soc Titul Creditos...
NYSE
JCT
LSE
89DU
Bank Mont.59
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés